Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@BrokenMoats

Broken Moats on X

SMR reactors last year or quantum...appears the current moments basket of trash stocks with a narrative that doesn't fit the companies is 3rd derivative ai drug discovery plays (genome, simulation software, etc). $TWST $TEM $SDGR $TXG and theres more My favorite is $WGS - opko rehash with key players from there somehow sitting on a multi billion dollar valuation currently. There were caught with billing schemes multiple times at Opko as well as other serious problems (see Philip frost and opko). A member of the board actually still sits on Frosts charity and the CEO was the CEO of Cathie Wood favorite Invitae, that went bankrupt a few years ago. The short story writes itself, seems like a CVNA almost where the setup is pretty opposite, and yet it probably continues to work against you
@KEDM_COM 2 clicks

KEDM.com on X

Alpine Capital @jdsdebruyn reduced semiconductor exposure and added hyperscalers after the June pullback, citing combined hyperscaler capex of approximately $416bn in 2025 projected to exceed $750bn in 2026. It initiated Oracle $ORCL, and concedes the entry has not worked yet: “Oracle’s price action since initiation has been disappointing, but we believe the valuation is attractive and the current view on Larry Ellison (co-founder) is probabilistically asymmetric given the entry point. Oracle can slow spending if AI reverses (which we do not think will happen).”
@BlueDuckCap

BDC on X

Just surfacing this one to demonstrate we are not and never were $snap absolutists. We will go long and short and when facts and circumstances change our opinion changes too. And NO - Specs will not be a mass market hit this holiday season. Too expensive and awk form. But here's the bull case from here: 1. FCF/Share is the metric mgmt now focused on. By definition that requires fresh cost and SBC discipline. 16% hc reduction and flat share count already in place. $500mn in opex savings about to flow through. 2. Ads biz stable enough. 9% growth in Q2. Guide implies so decel. But ad checks stable vs Q2. Decent enough. Some progress on ad tech. Only needs 5% growth next year to hit our numbs. 3. Sub biz $1.2B rr, growing 85%. Needs 50% growth next year to hit numbs. 25mn paid subs, still well below penetration threshold of 7-12%. 4. Specs tech is real. 7k+ patents. Real use cases. What's that worth? $META or $MSFT or $AMZN could buy Specs for the patents alone and pay $2B and it would be nothing to them but all the call optionality which could incubate until form factor is mass market. 5. Lets just say Specs is worth $2B to a strategic buyer or partner. That implies $snap 7.5B or $4.5/ share. In this scenario then FCF/share at SNAP goes to over $1/share, easily. So 4.5x FCF on a business still growing revenue mid teens. @evanspiegel Specs are cool. But can't keep spending $500mn a year on them. Bring in a minority investor please and lets make SNAP stock great again. @IrenicCap

Investor Letters

All letters

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 4 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 3 clicks
T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

T $144B
Value Investors Club

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

Another Haircut with Avy the Barber

SoFi’s stock case hinges on interest rates, tangible book value and private-credit loan sales after its $1.5 billion equity offering.

SOFI $22B
WHAT ARE WE DOING? “Contrarians At The Gate” 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

303 firms

Sectors

Ordered by how often our editor reaches for them.